New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.